ClinicalTrials.gov
ClinicalTrials.gov Menu

Change in Mindfulness in Borderline Personality Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03297840
Recruitment Status : Recruiting
First Posted : September 29, 2017
Last Update Posted : September 29, 2017
Sponsor:
Information provided by (Responsible Party):
Katharina Bachmann, University of Oldenburg

Brief Summary:
The current study aims to investigate the effect of dialectical behavioral therapy on mindfulness in patients with Borderline Personality Disorder. A treatment group will be compared to a waitlist control group.

Condition or disease Intervention/treatment
Mindfulness Borderline Personality Disorder Behavioral: Dialectical Behavioural Therapy (DBT)

Detailed Description:

Participants will be recruited from the Dialectical-Behavioral-Therapy (DBT) unit. DBT is a treatment approach that has been shown to be effective in the treatment of Borderline Personality Disorder. DBT integrates different psychotherapeutic interventions as well as Mindfulness Meditation exercises. Mindfulness is a meditation practice that can improve present moment awareness. When applied as therapeutic intervention mindfulness meditation can help patients to stay with their attention in the present moment, to be aware what is happening in the here and now, and to better identify and regulate upcoming emotions.

The current observational study investigates changes in symptom severity and mindfulness skills during DBT treatment. A treatment group will be compared to a waitlist control group. The two groups are predefined by routine medical care.

Symptom severity and mindfulness skills will be assessed at baseline (before treatment or when accepted for the waitlist) and after 12-weeks. A within and between group analyses will be performed.


Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Other
Time Perspective: Other
Official Title: Change in Mindfulness in Borderline Personality Disorder After Dialectic-behavioural Therapy (DBT): A Pre-post-comparison
Actual Study Start Date : May 4, 2017
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Treatment
Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
Behavioral: Dialectical Behavioural Therapy (DBT)
Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.

Waitlist
Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.



Primary Outcome Measures :
  1. Change in mindfulness [ Time Frame: Baseline and after 12-weeks ]
    Degree of mindfulness will be assessed by the Kentucky Inventory of Mindfulness Skills, German Version (KIMS-D). A within and between group comparison will be performed (treatment vs. waitlist).

  2. Change in borderline symptom severity [ Time Frame: Baseline and after 12-weeks ]
    Change in Borderline symptom severity is measured by the Borderline Symptom List (BSL 23). A within and between group comparison will be performed (treatment vs. waitlist).

  3. Change in overall psychiatric symptom severity [ Time Frame: Baseline and after 12-weeks ]
    Change in overall symptom severity is measured by the Change in symptomseverity is measured by the Symptom-Checklist-90®-Standard (SCL-90). A within and between group comparison will be performed (treatment vs. waitlist).

  4. Change in severity in symptoms of depression [ Time Frame: Baseline and after 12-weeks ]
    Change in overall symptom severity is measured by the Beck depression inventory (BDI). A within and between group comparison will be performed (treatment vs. waitlist).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Male and female BPD Patients from 18 to 60 years.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Borderline Personality Disorder
  • On the waitlist for DBT treatment or actually treated with DBT
  • Not previously treated with DBT.

Exclusion Criteria:

  • Severe psychiatric comorbidity e.g. psychosis, severe depression, suicidality

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03297840


Contacts
Contact: Katharina Bachmann, Psych.Msc. 00494119615 1506 Katharina.Bachmann@uni-oldenburg.de

Locations
Germany
Department of Psychiatry and Psychotherapy - University Hospital, University of Oldenburg Recruiting
Bad Zwischenahn, Germany, 26160
Contact: Katharina Bachmann, Psych.Msc.         
Sponsors and Collaborators
Katharina Bachmann
Investigators
Principal Investigator: Alexandra Philipsen, Prof. Department of Psychiatry and Psychotherapy - University Hospital, University of Oldenburg, Oldenburg, Germany

Responsible Party: Katharina Bachmann, Psychologist Msc., University of Oldenburg
ClinicalTrials.gov Identifier: NCT03297840     History of Changes
Other Study ID Numbers: Mindfullness in BPD
First Posted: September 29, 2017    Key Record Dates
Last Update Posted: September 29, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders